Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 1.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,486 shares of the biopharmaceutical company’s stock after selling 309 shares during the period. Tower Research Capital LLC TRC’s holdings in Royalty Pharma were worth $497,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Swedbank AB increased its position in shares of Royalty Pharma by 10.3% in the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after purchasing an additional 1,136,800 shares during the last quarter. Geode Capital Management LLC increased its position in Royalty Pharma by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company’s stock valued at $186,846,000 after acquiring an additional 46,765 shares during the period. Norges Bank bought a new stake in shares of Royalty Pharma during the fourth quarter valued at about $124,498,000. Charles Schwab Investment Management Inc. raised its position in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock worth $79,888,000 after buying an additional 130,025 shares in the last quarter. Finally, New South Capital Management Inc. raised its holdings in Royalty Pharma by 19.9% during the fourth quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company’s stock worth $75,436,000 after purchasing an additional 490,754 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

RPRX opened at $32.71 on Wednesday. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $18.86 billion, a P/E ratio of 22.56, a PEG ratio of 2.31 and a beta of 0.50. The stock has a fifty day moving average of $32.51 and a 200-day moving average of $29.50.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.69%. Royalty Pharma’s dividend payout ratio is currently 60.69%.

Wall Street Analysts Forecast Growth

Separately, Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.